ALX ONCOLOGY HOLDINGS INC

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	June 30,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$22,687	$16,373
Short-term investments	115,542	28,417
Prepaid expenses and other current assets	5,228	5,937
Total current assets	143,457	50,727
Property and equipment, net	166	1,200
Long-term investments	15,147	3,494
Other assets	2,050	3,625
Total assets	$160,820	$59,046
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,022	$4,914
Term loan, current	—	5,217
Accrued expenses and other current liabilities	11,754	14,422
Total current liabilities	14,776	24,553
Term loan, non-current	9,705	4,532
Other non-current liabilities	152	3,980
Total liabilities	24,633	33,065
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 138,216,247 and 54,388,022 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	138	54
Additional paid-in capital	894,988	748,716
Accumulated other comprehensive income (loss)	(224)	28
Accumulated deficit	(758,715)	(722,817)
Total stockholders’ equity	136,187	25,981
Total liabilities and stockholders’ equity	$160,820	$59,046

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.